BR0207253A - Polinucleotìdeo, polipeptìdeo isolado, anticorpo monoclonal, ou fragmento de ligação do antìgeno do mesmo, vetor de expressão, célula hospedeira, medicamento composição farmacêutica, e, utilização de um polipeptìdio isolado - Google Patents
Polinucleotìdeo, polipeptìdeo isolado, anticorpo monoclonal, ou fragmento de ligação do antìgeno do mesmo, vetor de expressão, célula hospedeira, medicamento composição farmacêutica, e, utilização de um polipeptìdio isoladoInfo
- Publication number
- BR0207253A BR0207253A BR0207253-0A BR0207253A BR0207253A BR 0207253 A BR0207253 A BR 0207253A BR 0207253 A BR0207253 A BR 0207253A BR 0207253 A BR0207253 A BR 0207253A
- Authority
- BR
- Brazil
- Prior art keywords
- isolated polypeptide
- pharmaceutical composition
- polynucleotide
- monoclonal antibody
- expression vector
- Prior art date
Links
- -1 monoclonal antibody Proteins 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 102000040430 polynucleotide Human genes 0.000 title abstract 3
- 108091033319 polynucleotide Proteins 0.000 title abstract 3
- 239000002157 polynucleotide Substances 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 239000013604 expression vector Substances 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000009702 cancer cell proliferation Effects 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
"POLINUCLEOTìDEO, POLIPEPTìDEO ISOLADO, ANTICORPO MONOCLONAL, OU FRAGMENTO DE LIGAçãO DO ANTìGENO DO MESMO, VETOR DE EXPRESSãO, CéLULA HOSPEDEIRA, MEDICAMENTO, COMPOSIçãO FARMACêUTICA, E, UTILIZAçãO DE UM POLIPEPTìDIO ISOLADO". A presente invenção refere-se a uma proteína inédita que modula a proliferação das células cancerosas. Graças às proteínas codificadas pelos polinucleotídeos descritos no presente pedido, também é possível determinar o grau de malignidade de células em proliferação anormal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0102801A FR2821624B1 (fr) | 2001-03-01 | 2001-03-01 | Nouveau polynucleotide utilisable pour moduler la proliferation des cellules cancereuses |
| PCT/FR2002/000740 WO2002070700A1 (fr) | 2001-03-01 | 2002-03-01 | Polynucleotide utilisable pour moduler la proliferation des cellules cancereuses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0207253A true BR0207253A (pt) | 2004-02-10 |
Family
ID=8860611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0207253-0A BR0207253A (pt) | 2001-03-01 | 2002-03-01 | Polinucleotìdeo, polipeptìdeo isolado, anticorpo monoclonal, ou fragmento de ligação do antìgeno do mesmo, vetor de expressão, célula hospedeira, medicamento composição farmacêutica, e, utilização de um polipeptìdio isolado |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7214533B2 (pt) |
| EP (1) | EP1368474B1 (pt) |
| JP (1) | JP4190291B2 (pt) |
| KR (1) | KR100869190B1 (pt) |
| CN (1) | CN1289670C (pt) |
| AT (1) | ATE351906T1 (pt) |
| AU (1) | AU2002335492B2 (pt) |
| BR (1) | BR0207253A (pt) |
| CA (1) | CA2437535C (pt) |
| CZ (1) | CZ20032670A3 (pt) |
| DE (1) | DE60217651T2 (pt) |
| ES (1) | ES2279877T3 (pt) |
| FR (1) | FR2821624B1 (pt) |
| HK (1) | HK1065334A1 (pt) |
| HU (1) | HUP0303312A3 (pt) |
| IL (1) | IL157091A0 (pt) |
| MX (1) | MXPA03007694A (pt) |
| NZ (1) | NZ527261A (pt) |
| PL (1) | PL204844B1 (pt) |
| RU (1) | RU2307666C2 (pt) |
| WO (1) | WO2002070700A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010132479A2 (en) | 2009-05-11 | 2010-11-18 | Cytotech Labs, Llc | Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| CA2832324C (en) | 2011-04-04 | 2022-03-15 | Berg Llc | Methods of treating central nervous system tumors |
| KR102279451B1 (ko) | 2013-04-08 | 2021-07-19 | 버그 엘엘씨 | 코엔자임 q10 병용 요법을 이용한 암 치료 |
| KR102370843B1 (ko) | 2013-09-04 | 2022-03-04 | 버그 엘엘씨 | 코엔자임 q10의 연속주입에 의한 암치료 방법 |
| ES2878451T3 (es) * | 2014-11-14 | 2021-11-18 | Voyager Therapeutics Inc | Polinucleótidos moduladores |
| US11951121B2 (en) * | 2016-05-18 | 2024-04-09 | Voyager Therapeutics, Inc. | Compositions and methods for treating Huntington's disease |
| KR20240056729A (ko) | 2016-05-18 | 2024-04-30 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5637456A (en) * | 1995-02-17 | 1997-06-10 | The University Of Texas, Board Of Regents | Rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation |
| WO2000069454A1 (en) * | 1999-05-17 | 2000-11-23 | Board Of Regents, The University Of Texas System | Suppression of endogenous igfbp-2 to inhibit cancer |
-
2001
- 2001-03-01 FR FR0102801A patent/FR2821624B1/fr not_active Expired - Fee Related
-
2002
- 2002-03-01 DE DE60217651T patent/DE60217651T2/de not_active Expired - Lifetime
- 2002-03-01 PL PL365226A patent/PL204844B1/pl not_active IP Right Cessation
- 2002-03-01 AT AT02748337T patent/ATE351906T1/de not_active IP Right Cessation
- 2002-03-01 NZ NZ527261A patent/NZ527261A/en unknown
- 2002-03-01 CN CNB02805623XA patent/CN1289670C/zh not_active Expired - Fee Related
- 2002-03-01 EP EP02748337A patent/EP1368474B1/fr not_active Expired - Lifetime
- 2002-03-01 ES ES02748337T patent/ES2279877T3/es not_active Expired - Lifetime
- 2002-03-01 MX MXPA03007694A patent/MXPA03007694A/es active IP Right Grant
- 2002-03-01 HU HU0303312A patent/HUP0303312A3/hu unknown
- 2002-03-01 BR BR0207253-0A patent/BR0207253A/pt not_active Application Discontinuation
- 2002-03-01 AU AU2002335492A patent/AU2002335492B2/en not_active Ceased
- 2002-03-01 KR KR1020037011444A patent/KR100869190B1/ko not_active IP Right Cessation
- 2002-03-01 JP JP2002570725A patent/JP4190291B2/ja not_active Expired - Lifetime
- 2002-03-01 CA CA2437535A patent/CA2437535C/fr not_active Expired - Fee Related
- 2002-03-01 US US10/467,436 patent/US7214533B2/en not_active Expired - Fee Related
- 2002-03-01 WO PCT/FR2002/000740 patent/WO2002070700A1/fr active IP Right Grant
- 2002-03-01 CZ CZ20032670A patent/CZ20032670A3/cs unknown
- 2002-03-01 RU RU2003129163/13A patent/RU2307666C2/ru not_active IP Right Cessation
-
2003
- 2003-03-01 IL IL15709103A patent/IL157091A0/xx unknown
-
2004
- 2004-10-20 HK HK04108190A patent/HK1065334A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2279877T3 (es) | 2007-09-01 |
| NZ527261A (en) | 2005-06-24 |
| CA2437535C (fr) | 2011-05-10 |
| JP4190291B2 (ja) | 2008-12-03 |
| JP2004527240A (ja) | 2004-09-09 |
| IL157091A0 (en) | 2004-02-08 |
| CN1289670C (zh) | 2006-12-13 |
| ATE351906T1 (de) | 2007-02-15 |
| KR20030090655A (ko) | 2003-11-28 |
| FR2821624A1 (fr) | 2002-09-06 |
| RU2003129163A (ru) | 2005-02-20 |
| US7214533B2 (en) | 2007-05-08 |
| PL365226A1 (en) | 2004-12-27 |
| AU2002335492B2 (en) | 2006-11-02 |
| KR100869190B1 (ko) | 2008-11-18 |
| EP1368474B1 (fr) | 2007-01-17 |
| US20040197783A1 (en) | 2004-10-07 |
| HUP0303312A3 (en) | 2012-09-28 |
| WO2002070700A1 (fr) | 2002-09-12 |
| MXPA03007694A (es) | 2004-03-16 |
| CZ20032670A3 (cs) | 2004-04-14 |
| CN1494591A (zh) | 2004-05-05 |
| RU2307666C2 (ru) | 2007-10-10 |
| CA2437535A1 (fr) | 2002-09-12 |
| DE60217651T2 (de) | 2007-10-18 |
| DE60217651D1 (de) | 2007-03-08 |
| PL204844B1 (pl) | 2010-02-26 |
| FR2821624B1 (fr) | 2004-01-02 |
| HUP0303312A2 (hu) | 2003-12-29 |
| HK1065334A1 (en) | 2005-02-18 |
| EP1368474A1 (fr) | 2003-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0418766A (pt) | anticorpos e moléculas derivadas destes que se ligam às proteìnas steap-1 | |
| BR0213303A (pt) | Proteìnas de ligação de alvejamento direto | |
| HUP0500345A2 (hu) | Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására | |
| NO985150D0 (no) | Antigenbindende fragment som sµrlig sporer kreftceller, nukleoid som koder nevnte fragment, samt bruk av dette ved forebygging og pÕvisning av kreft | |
| BG100771A (en) | Hematopoeic protein and ways and methods for its preparation | |
| CY1111283T1 (el) | Μορια με παρατεταμενες ημι-περιοδους ζωης, συνθεσεις και χρησεις εξ αυτων | |
| BR0306444A (pt) | Uso de anticorpos anti-tnf(alfa) e outra droga | |
| BR9914116A (pt) | Composições e métodos para imunoterapia especìfica de wt1 | |
| ATE299180T1 (de) | Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren | |
| TR200000654T2 (tr) | KAY-Yeni bir bağışıklık sistemi proteini. | |
| BR0209254A (pt) | anticorpos de bloqueio cripto e usos dos mesmos | |
| NO20084906L (no) | DNA-sekvens som koder for tumornekrosefaktorrelatert ligand (TRELL), vertsorganisme transformert med slikt DNA samt TRELL, fremstilling og anvendelse derav ved fremstilling av medikamenter og antistoffer | |
| ATE151113T1 (de) | Fusionsproteine von monomeren und dimeren von antikörperfragmenten | |
| NO20011759D0 (no) | Flt4 (VEGFR-3) som målmateriale for tumor-avbildning og anti- tumor-terapi | |
| BR0207253A (pt) | Polinucleotìdeo, polipeptìdeo isolado, anticorpo monoclonal, ou fragmento de ligação do antìgeno do mesmo, vetor de expressão, célula hospedeira, medicamento composição farmacêutica, e, utilização de um polipeptìdio isolado | |
| WO1999002545A3 (en) | Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers | |
| PT1087993E (pt) | Péptidos fas e anticorpos para modular a apoptose | |
| GB2278357B (en) | Humanised antibodies directed against A33 antigen | |
| ATE273388T1 (de) | Veränderte menschliche c3-proteine | |
| ATE205532T1 (de) | Zellzyklus-unabhängige, gliomaoberflach- spezifische, menschliche monoklonale antikörper | |
| BR9914892A (pt) | Composição farmacêutica, contendo fragmentos de um dna de codificação de proteìna antigênica dotado com efeito antitumor | |
| ATE450272T1 (de) | Rekombinantes adenylat-cyclase-toxin von bordetella induziert t-zell-antworten gegen tumorale antigene | |
| ITRM920506A1 (it) | Regioni antigeniche dei complessi tpl e anticorpi diretti contro di essi. | |
| AU2002360392A8 (en) | New gene expressed in prostate cancer and methods of use | |
| BR0214288A (pt) | Anticorpos monoclonais especìficos para tumor, ácidos nucléicos que codificam tais anticorpos e método para redução de proliferação de células neoplásicas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |